Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma-Reference-Cited by-同舟云学术

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

Published:2018-09 Issue:6 Volume:119 Page:707-712
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bellmunt Joaquim^ORCID,Lalani Aly-Khan A.^ORCID,Jacobus Sussana,Wankowicz Stephanie A.,Polacek Laura,Takeda David Y.,Harshman Lauren C.^ORCID,Wagle Nikhil,Moreno Irene,Lundgren Kevin,Bossé Dominick,Van Allen Eliezer M.,Choueiri Toni K.^ORCID,Rosenberg Jonathan E.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0261-0.pdf

Reference41 articles.

1. Iyer G., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.

2. Sadeghi, S. & Garcia, A. J. Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder. Semin. Oncol. 39, 608–614 (2012).

3. Sjödahl, G. et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS. ONE. 6, e18583 (2011).

4. Williams, S. V., Hurst, C. D. & Knowles, M. A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 22, 795–803 (2013).

5. Garraway, L. A. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31, 1806–1814 (2013).

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of targeted therapies for advanced urothelial carcinoma;Exploration of Targeted Anti-tumor Therapy;2024-06-21

2. Distinct Driver Pathway Enrichments and a High Prevalence of TSC2 Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis;International Journal of Molecular Sciences;2024-04-25

3. Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma;Medicina;2024-03-31

4. Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data;Irish Journal of Medical Science (1971 -);2023-11-10

5. Biomarkers determining treatment tactics in metastatic urothelial cancer;Cancer Urology;2023-08-13